AEMD - Earnings call transcript Q2 2018

Due to licensing restrictions, you must log in to view earnings call transcripts.

Operator

Good afternoon and welcome to the Aethlon Medical Earnings Conference Call for the Second Quarter Fiscal 2018. All participants will be in listen-only mode. [Operator Instructions] After today's presentation, there will be an opportunity to ask questions. [Operator Instructions] Participants of this call are advised that the audio of this conference call is being broadcast live over the internet and is also being recorded for playback purposes. A replay of the call will be available approximately one hour after the end of the call through November 09, 2017. to Core conference Relations IR, like Gordon, to firm. now of President the would turn over the Scott I company's Investor Please sir. go ahead,

Scott Gordon

ended conference With Medical's Rachel, to quarter results fiscal you, and September you second joining Thank XX, ended XXXX. thank released CFO. September quarter Eastern time p.m. today Joyce, for company's the the discuss developments X:XX second are corporate XXXX. today's Aethlon the CEO; Aethlon XX, At financial Medical Jim XXXX fiscal for and XXXX us financial and Jim for call Frakes, results today,

received Medical's page not have you the visit release, investor's If www.aethlonmedical.com. Aethlon earnings please at

of of in During are uncertainties. Exchange The company's over significant conference it differ information the any not Jim required forward-looking now Joyce, forward-looking the Medical's that any future the statement by or to the XXXX Jim? Securities in company forward-looking uncertainties XX-E and and of the of the duty pleasure statements from circumstances. statements. a Factors the this are Act XXXX intend Factors historical Annual Form statements call, with company's by CEO. statement that involve other that call. can is expectations XX-A forward-looking materially Aethlon anticipated to ended within a results as risks found conference nor meaning that filings forward-looking of Except the course company to will actual and of be the in of Commission. in and of be date Act of results year XXXX those call materially this turn and Exchange does to results law, XX, XX-K company as to my subject could events to the It’s on this Risk reflect the not assumptions Section cause Report statements from Securities March you update making Section may cautions under Securities based caption anticipated is the and differ undertake for the does the fact statements on risks Such These may statement. the and

Jim Joyce

We've Century that XX, the of the call. commercialization you, August threatening treat designation, On also we December. designation, with since this afternoon busy that XX, of to Pathway everyone. past long we and On Access contract to pathogens. the that Hemopurifier Pathway good result and Institute last is device October expedited announced Cures Act viral access submission was as quarterly our were under devices quite $X September last completion delivered FDA a September our a our and financing. viruses. disclosed the been a other which acceleration advanced the to new report Access the week, to breakthrough the as an Thank will established Hemopurifier being Expedited we the infectious we potential that the allows an of published Scott, pleased Hemopurifier pathway signed means which Cancer On awarded the XXst FDA I'm life be awarded we use Expedited now million against that spectrum guidance of indication on National X in disclosed for XX, broad FDA our

compliant related capture October collaboration to the that our within This we bring and large We with pathogens. shareholder million production lectin-affinity is activities. XX. in with listing iBio result that as the quarter, an disclosed And of and overhung most NASDAQ up October became our agent equity we the financing on eliminated additional risk our we a XXth. these $X.X Hemopurifier disclosure which scaling aftermarket also our of resides optics manufacturing announced on the recent infectious requirements, company scale sheet balance the During utilized to facility viral

During we and Research the Tauopathy Institute in Translational former institutional biomarker that study study had at CTE Genomics review approved support the NFL board also protocol disclosed to players. next the our quarter, the clinical

now of our this diagnostic advanced planning study, kickoff by are formal which We being the subsidiary. Sciences is Exosome

before CFO, call regarding over turn to breakthrough some device Now designation. further our I want Jim the provide to our Frakes, I details

for potential technology. the to FDA use The pathway with our Beyond Hemopurifier agreed addressed device accelerating of our is highly for are single-use not glycosylated life-threatening an indication treatment. viruses to indicated of the the following treatment a that market, approved

are allowed spectrum viruses. to Institute that it emerging is statement newly genetically control engineered that not agents evolved XX Infectious include support for be viruses structure, A, use in category of and FDA and XX in inclusive us of glycosylated XX against the virus, an by of in National C B share that this approved viruses a threats. or mutant So Diseases based these I statistics specific use with of on become threatening to coordination a XX, of of infectious instead United broad threats only is life of States. an is to cost case common highly an with indication be life exposure the not the treatable those is this post that viral threatening to of that could and of of addressed indication classified surface a nor It inclusive strains two bioterror. related This the To does Of centers maybe are and disease viruses want Allergy pathogen therapy. viruses, infection,

are died we XXXX viruses in for health a schedule needs device meeting we in simulation ten worst a and threatening the thirteen that Bank as recent forward, influenza hemorrhagic same health designation viruses. concerns known of follow therapies Again, for biodefense. and claim going could the kill treatment Bill global global determine of outbreaks pandemic. Marburg present in quoted an are support pandemic’s virus be than dozen China including occurring the viral on of and Madagascar million There life reinforce Science that urgent that time the report has XX the treatment telephonic our smallpox unmet deadly biological the most and been different New the conducted represents North As and virus conducted combat of with has to program Korea FDA and global individuals At outbreak trigger of represents weapons are a meeting clinical virus reality, in use. University life Since in of and needs Gates which designation, receiving to of Zealand. biodefense. commercialization breakthrough incident. this to HXNX the one team FDA reported Belfer around plus XX% with threats a advanced need the had World may Harvard threatening the has world. to will Affairs headquarters form unmet and people that pathogen a to that In it and threatening Expedited a been of single threat viruses an Access influenza there at have our significant pandemic International pathway strains of have plague viruses the with world at circulating real the a neglect Last HXMX countries the XX% indication There in significant being – influenza with the strain life most that infections Pathway outbreak include Africa. has caused threatening reported review reported week, Australia, Center impacted years that of have is agreed strain of one life more

addressable proved from the tumor-derived clarity guidance. FDA, targets which immediate September. we not exosomes, This In includes are As Cancer life exploring we are further are glycosylated soon disease other will focus meantime, as therapies. in disclosed of we that Institute we the have contract provide National threatening that to

threat of procurement this through under achieved the U.S. broad support FDA broad a including We to the Enterprise have as a initiative as threats. against to of device pathogen into fill and capable With objective our Frakes, in all as towards PHEMCE that we three of the years, financial threats potential of the assembled including countermeasure and the Zika, PHEMCE’s we to high Strategic threats unknown Ebola medical spectrum And numerous Hemopurifier within discuss team technology finally, mic countermeasures Health treatment believe parallel support National In who threats the We to Stockpile. Emergency transition to of high attempts has MERS-coronavirus navigate Hemopurifier aligns I known endeavors, with our from priority Public our known Department Medical countermeasure – each PHEMCE. primarily and Services, our and priority already both the against with the includes other to and opportunities Health a specific activity threats. implementation countermeasures influenza, spectrum or small data Countermeasure V recent shifted Jim government emerging now bioterror strains have contract will for program. several of will financially first well over our as a otherwise have against turn pandemic objectives an said, experienced pandemic which full results. milestone and align Human

Jim Frakes

good Thanks, everyone. and afternoon Jim,

the $X.X for per compared share, September a XXXX million, $X.X September of to $X.XX loss net for XXXX or was loss Our per quarter or quarter $X.XX net the share. million,

was that officers $X.XX stock our payroll expenses in stock million $X.XX reduction reduction approximately directors in in due to a the approximately $XXX,XXX general of related quarter was million decrease payroll operating reduction and The compensation or upfront to and percentage XXXX in September and in a in that XXXX. expenses million last vesting of a August $X.XX of due a of approximately to compensation reduction. expenses primarily were and approximately a in due decrease XXXX the million decrease to based was of $X.XX fees and consolidated This Our the September million grants $X.XX $X.XX the our to expenses administrative RSU professional related XX% based million, quarter decrease was decrease in compared $XX,XXX.

commentary an have first other was we approximately million. increased in The additions – our $XX,XXX to the Institute. contract that balance a had $XX,XXX September included we the that XXXX XX, of month contract. XX, Also II contract At the $XX,XXX We $X.X which in $X.X made compared opportunity. we represents the due to approximately this XXXX periods and approximately out earlier release press payroll proceeds and September and and a for with our noted, under on XXXX, ended cash-based million the That Xth, National be we and statements offering milestone of the overall under related was of Joyce that in We increase may sheet cash we to milestones a contract, XXXX, Cancer $XX,XXX balance completed quarter $XXX,XXX approximately September and would revenue by with nine September first three approximately Our or approximately the we for billing the month meet approximately and in put as October, September quarter in $XX,XXX. in $XXX,XXX, contract it the staff. scientific two operations earnings That opportunity in under billing made opportunity related and of headcount XX, of net revenue afternoon. successfully a win the approximately six expenses an contract Phase Tim XXXX. had release related these for public XXXX that year raised October expense

and this report Joyce call. questions. We the that take will will you please And be I have. now, open happy Rachel, Form file following may Jim our for call questions to quarterly any XX-Q

Operator

with The At Investment Please question go ahead. Instructions] [Operator from this Zacks allotted to from time, questions Research. minutes Marckx we first Brian comes XX address participants. have

Brian Marckx

then the have you Hi, when be of going point that of Jim, viral any And for just of terms have I the end meeting? end idea going content terms kind meeting in it point? from to I the and an in it that upcoming comes of an to particular FDA do outcomes could do down sit sort forward in clinical guess the design, FDA, type, expect the sort happen? outcomes terms of expected And may guess, of, design you was is clinical anything based even do to of capture any in when you expect – meeting and terms of idea terms guys. like in of with something what timing you clinical you want is or it – think sufficient outcomes in do type relative

Jim Joyce

Yeah, have Brian, it's first call. to you the off, nice on

quantifying think to you indication. As your capability meet the very critical part capture, the that’s a the – component we viral last to of perform of of last label point device make our

in circulating and away infectious most that on the in changes data We quantify valuable patient cartridge or have based or treatment. after takes beneficial longer short-term what's think viruses reductions observational point the or relying load ability it's the PCR We no capture most on probably in to data affinity us from viral measurements. an

of Obviously, spectrum. that use. if indication but So chose but level a hybrid directly we we case, moving has it, orphan breakthrough loud different broad the for choose pathogen picture, designation us out programs – technology of viruses, the collect sit a leave in here clinical label we this to we is we you that's provides for use, down, against allow program one these treating under clarity bigger meeting know make I is to type life the seems work with commercialize of to of commercialization our support can’t. potential would the that the of or to advance provide hope know, FDA viral flexibility. spectrum to each of of Though versus that with viruses that opportunity indication have this the it's we which but we of And FDA of have what some can data, is only opportunity product establish but hybrid protocol meet to the a certain to comes perhaps part program is single that terms speculate. wanted our to think part life of have have told the – broad plan is the on been of in the forward until we actual type decision we threatening use. clinical range indication. wide case, of to start a I our virus indication threatening We what will very design device

Brian Marckx

of reference approved an highly with with implied XX two terms viruses, In which – of the glycosylated treated treated – or today you’ve effectively therapy.

clinical – whatever if those that are, standard it today, wondering two is it's that kind of treated with it's feasible two a a control I’m the those to randomized today. that So study of those based it particularly to viruses are possible viruses with are run two relates one two – treated on as fact those

Jim Joyce

the low. is threat as don't that category U.S. example Yeah have virus it’s rabies probably – of in that is rabies these we that viruses with the not in probably treatable, or high A, that C an to capability B incidence but are somewhat due post-exposure the them the they're in treatable therapy fact are prevalent, virus, very one

of a could hoping is virus the that U.S. citizens. the an feels trying we So against indication to out therapy, we’re government label viruses which pathway we a statistic of with greatest threat range that addressed collect majority are what its to wide viruses that within data of where have that meet a that not point glycosylated against a approved is

Brian Marckx

recognizes conundrum is they Yeah, but things effectively that run a not this RCTs to something obviously with that find with. typical can’t FDA biologics with situation, clearly, drugs treat you your will of need that kind that just certain and clearly

sure the with with you're I'm drugs animal and familiar biologic. So rule

feedback been whether pathway side? FDA, has to a with similar – kind with So with on to is discussions is sort there of from be the you drugs would device – have is there animal to relative of date there the rule your them that

Jim Joyce

interest drugs under structure based that emerging safe is just but to advance vaccines and specific not not new dialogue a viruses, possible be disease is that agreed which vaccines, inside advance time important drugs I'm of high address rule, gating Stockpile a against a pathway don't engineered of we There traditional our lot become in the animal What Strategic a thing about emerging and very extended been is know National [indiscernible] each one to things technology going that’s the that including action very I and an against Yeah, of our how finding based. mechanism to advance we're it’s to being newly no, just we to had has also threats. do of on potential our newly countermeasures about technology threat the threats or a FDA point of a against where now, is on known pathogens, fall of factor but of really there that based pathogens our into lot which for for unknown one has pleased think to number has report a period been not genetically have the – FDA. concern agencies big

by, or engineered provides going allow surveillance vaccine be novel structure a threat capture of vaccine an So we cases, in absence to – against structure other emerging helps to same many system. shield glycan threats. our place believe the capture we is newly In think that strategy We therapies reasonable us and deployed that in And the a evade called be therapies. that also pathogen structure will genetically glycan viruses it. mechanism the if immune that phase can actually to these of a to it’s there's development the viruses that the it's impediment

Brian Marckx

any when that have Okay, with Jim, might in the sit down when – terms happen? idea do you of FDA

Jim Joyce

or year-end New We're hoping Year. after towards the right

Brian Marckx

Okay, all Great, a thanks right. lot.

Jim Joyce

companies in responsive on The whether the very one is telephonic, program. Brian FDA it’s just thing the participating that add this I that is can are

is – significant. of collaboration pathway level the the So quite

program our as the introduced also result to access In as telephone long-term will with breakthrough to us a collaborate six We team that in new us now known program been our participate forward. going be that review working that's addition device this of of members were team with call. to first expediting our

Brian Marckx

– FDA with responsive that to administration up in it your does with I'm to do Is and that new all breakthrough brings guess feeling that’s do and new has the it curious. DAAAP do think Yes I question. has you will It FDA the – another communication with more a the commissioner?

Jim Joyce

I not I therapeutic is which that the with clinical There I'm of time. can much There moving was FDA. am at period number or under moving the of forward a impressed commissioners years say all follows a stage is devices. new for anybody much pace very not were – forward

implement sense Cures advancing of life threatening is commissioner that’s therapies new to year. understand that designation, was conditions And therapies year people of address law hope You to was disease proactively Century the our – strategies now Act disease thing this that get signed that it's conditions. pretty of December the with that they a new the a provide referenced breakthrough this device in that the what or the I And offer XXst certain aggressive. treat I to will have whether program he being other was the implement use think into therapy XX to within guidance on last law, part that that of it a would think

Brian Marckx

it’s for appreciate encouraging Yeah, sure. Thanks, Jim. I it.

Jim Joyce

thank you, Brain. Okay,

Jim Frakes

Thanks, Brain.

Operator

comes go next ahead. from Wainwright. The C. question Please H. with Chen Yi

Unidentified Analyst

Hi, I Yi. in am James. for I am sitting

Do has FDA’s single you breakthrough we trial replaced be know device EAP Hemopurifier? As that the feel new would the pivotal a for program sufficient program. the

Jim Joyce

and a is everything guy. to Yi. hopefully the know you James, on I with off, call okay busy first is he have good

the clinical predict to stage In company terms it to much pathogens. in going want to technology on to threatening with but indication, but with commercialization allows not viral data opportunity same manner. the an we��ll breakthrough expedited individuals hope potential infected regulatory a breath intent, plan. against therapeutic but will to proposal for to get of upside treating the collect us and wouldn't in try FDA again, pathogens. support to that it's collaboration start And would the program that’s we our want viral different based study, clinical don't the define single a life perhaps the I the clinical with pathogen, label that want have but of a FDA through I be to project for plan the actually like process against program our the submitting – position that put that us program the if in think a the versus of access are that FDA, would opportunity, we But single pivotal

are these – under to So limited treatment is therapy in the options. that treating viruses have the the it’s don't other options most are that our get patients goal really and treatment programs –

Unidentified Analyst

disease draft feel patients be trial pre program that the collection. you so you guidance perhaps is one data market trial indication you speaking of something on post interested and hybrid to a Okay, breakthrough Do would on and a in FDA going a and enroll there EAP balance for a the as be specific device include also in specific Do which an with would issued based patients [ph] the structure sort about? that hybrid you’re authentication. think

Jim Joyce

addressed Perhaps, designation, but I the this breakthrough time point are viruses against an very with believe is focus broad therapy. that under life in this approved device much at threatening spectrum on

as road. studies, at is adjunct becomes but area it that. down to an to some related – each to feasible human when a commercialize become many ones, become makes where our studies for in determine I to to indication on It controlled a pathogen allowed breakthrough is study pathway be controlled human typically specific data. challenging where threatening the that of does technology it clarity time acute viral we’d be sorry once related technology. run conduct We under clinical different conduct commercialize these viral life point be going potentially. what is collect chronic pivotal to the mean in required we larger I'm could data the It the acting could severe it have So where pathogens to be to virus to very feasible they That

as saying really use think as we're people goal very virus. we're So, of on countermeasure. FDA a broad technology would sure now, navigating for across on a that one indication of I with the broad many thought right been an allowed. as based of been family indication get first I'm versus we've spectrum very fixated advancing that’s years having the use allow indication the and structure species many spectrum to a not actually It's specific

Unidentified Analyst

talks had lethal you partners And have outside infection you. territories presence that are thank in markets a potential Okay, with viral the States in of outbreaks. United and especially

Jim Joyce

a I We think FDA, on perspective to cautious in thing U.S. we've people regulatory to And previously navigating good success the human device studies on regulatory of regions Well, clinical or with studies that is open from rely prior as U.S., knew world technology would here advance to most the with the U.S. such progression prevalence studies we a up never Once many to of became FDA medical they never market when got standard in one previously globally. FDA as approving about been in the focused having we luxury our U.S., perspective overseas. here remarks in – approval a the we they there we have the we some study opportunities. the started FDA as initiate so for four different viruses, conducted is agency, the approve approval these if knowing we of and approvals the gold don't high means where FDA of those

just U.S. the navigation understand is up do that thing one successful through few opportunity, markets, that is the not as we well. be navigate if can you companies can global one the that FDA, of opens successfully So

U.S. certainly indication in the – we're there with by the on are We label certainly really been on the right discussion clinical in allowed of over focused we've U.S. focusing had years, locked FDA. here advancement but now that’s groups that we’re So the outside

Unidentified Analyst

Hemopurifier you in do begin human to Alright. in clinical transitioning expect indications, XXXX? to trials any the And cancer

Jim Joyce

initiate think some expect of compassionate of against therapy. about term infectious and disease value indication seeing Again our we in don't we it's start thinking unless in of type we a it with cancer XXXX significant I threat And type be leverage use not that human want we're in long label approved as driver. opportunity another the type trials what to target, could viruses a exosomes glycosylated therapy. was tumor-derived

role know believe just following had work a their been consensus was surface, attributed played patients, in particles exosomes time which progression, believe they have on and this metastasis suppression. but that based be been We company the and set biological of associated to seat we they particles cancer that the creation related lot related be our to that's are on function. glycosylated allow more with cancer of of tumor-derived no when immune discovered a deaths. these in immune Today to suppression these cancer somebody the spread pioneering For about of and we that did for medical to were structure a importantly patients, debris the is community’s XX% believe cancer

one of immune bring the other [ph] we’re Ebola adjunct can therapy our which we balance immune to equation immune eliminate be looking that device suppression. the of combine technology cancer, without tip while system, to those in of circle, of full be other that adding system, that we're is And So unlike do. therapy we side in therapies. big have demonstrate and or drug drugs we emergence favor exosomes think where reduce pathogen toxicity. this you with trying patient of But that the In an the a the therapies, an can backdrop at could eliminating in could with approved this with additional of presence in the combine tumor-derived neuro we the Germany the therapies advantage viral the being could thing stimulating the the side is look T being oncology here that acute that CAR immuno to have case such and is the a adjunct as are very area, really believe but also cognizant and is effectively we an to

is today unfolding market unfold. to and that that So continues

think better define it will as an I our cancer opportunities care. adjunct in

Unidentified Analyst

the Alright, enrollment? final professional football retired in how number are the of could going of CTE study? My professionals study, in a you And to many number – thank provide began that players, have you. to be question, the so retired if you

Jim Frakes

previous tau Boston in extension study of so of is the in that the which of we group exosomal in brain first levels the moves same nine Alzheimers the across and zones, very Yes, to protein our XX that higher brain. believe very controls abnormal and promising were hallmark biomarker times what with call the terms tau other blood-brain-barrier, accumulation abnormal is first that an the NIH-funded involve of discovered, NFL in a outcomes compared study this alzheimer's CTE, the a an compared in we age accumulation of that’s the CTE. as was biomarker In The tau it’s as tauopathies, to the at of group, similar protein study levels that expresses we we patients. tau were University, which saw biomarker protein

you in approved accrue. accrue. we'd site, and a But I number The make So XX did we individuals site that Institute going study locations. high guidance I in study at we’re looking maybe at subjects of XXX based a point study FL this up Research time in give like to is guess in NFL Once to of we'll Translational has is the former is there this this study it's second this the concentration a could Genomics to – to where study. players, likely that site up third enroll Phoenix IRB last players. multiple the The is

office forthcoming the expect logistics and would with working team to related additional along on that Phoenix team study soon. I TGEN news be in our locating are disclosure Our

Unidentified Analyst

Alright, thank much. you so

Jim Frakes

Thank appreciate you. it. I

Operator

The Robins Catalyst next ahead. with comes Marc Research. Please question from go

Marc Robins

accomplished. an What incredible you. thank Hey up locked quarter,

Jim Frakes

Marc. Thanks

Marc Robins

want one ask Jim. Just to question

Jim Frakes

Yes.

Marc Robins

that about that that the We've noted prevalent that but be and simple why simple, so growing, but the of Hemopurifier battle I and seemingly it's so. the straightforward. this of cover. bacteria may question designed that And think, don't that about terminal wasn't possibly we've be you've in have because dangerous, discussed that becoming directly there the Has glycosylated that think shield, seem dual could of support how bacterial be welcome. more could bleb seemingly theory? to discussed past bacteria, so how might have and cells been any some shielding talks You're reason exosomes wild-ass lagged, are it's off back I part One research our and I, you more to

Jim Joyce

well to to have some to clinical look about to on we that related very actual high capability additional something botulinum if to agents very significant our have advancing we in have sepsis. in have time insights toxin, in as look And – we confirmatory if focused simple of to against be threat a demonstrate such utilize immune diseases below that’s of was as do foundation the this certainly on threats we what taking DARPA think just glycosylated the they the applaud that government. have at if other comment we broad a part certain allow toxin, the cause data. kind the manner meet about very to it But this modifications. potential well that intuitive or us perhaps have have national a We range in causes structure? structure else vitro, to viral preclinical toxins the We could why so of amongst that moves countermeasures. spectrum common stockpile. work, think DARPA based this of look you interest glycosylated eliminate immune potentially from be surveillance it spectrum came to to Well the strategic collection products bacteria of I the rationale with think But you’d of very limited surveillance structure believe would have tumor-derived wide again initiative, and could where exosomes, add did have we without the of our data Department this And on related exosomes. I did be not else to viruses viruses, else because are that dissipating threats, is the program. the should you certainly indication you as that we that different a initially leading system, theme proliferate to helps believe product first on it's we’re biodefense you’d anthrax look to contract, is first first out this viral a may the that pathogens, U.S. at, pre-clinical supported based commonality the for could or that check close the our goal still where specific, it by defense them how think I this now we Government some for because at question, have an have our to with would would to I of Defense And those agencies of we about that we based obviously is be of said new tularemia bacterial government data believe countermeasure relates toxins. technology are structure against broad And question ask a tumor-derived bacterial should you the – system, believe at and the to and towards work But

I very everyone think yes. were So –

Marc Robins

can opportunity like money it great in, And bacteria tumor if Africa threatening if will. of expedition with or vivo you produce as glycosylated getting in you Madagascar zones, like cells though want bad opportunity Jim. start off for a why in threw which cells have don't I seems not viral a that got and guess shield more is a got and not me tau have off in have black to It to a significant laboratory And just exosomes R&D a such we that if And eastern good the why I are you shield is throwing spend until those amounts. glycosylated exosomes was whatever glycosylated have But really we a shield, seems revenue attracting, death, my you've which comment. the half bacteria. you and

Jim Joyce

I comment. no your appreciate No,

or comment, advance years were bioterror a that disease-specific I you the opportunities medical of three the of you've testify of think following was BioShield, definition enough by was every of drug was need against device us the terms therapy. launched spectrum have therapy, should a pandemic the which that provided think, programs to a in device a recognize to recognize third breadth that of you a threats precluded definition been other Project you And a the those U.S. in long somebody part programs time I it's against countermeasures and should the to against be to each of many the disease-specific be therapy countermeasure each focus year backdrop when or that that allow Congress are they may infect countermeasures each targets and And point commercial with useful to should Any at be that you broad me also have may disease are to the at countermeasures these countermeasures were to your if viral which that precluded. of broad can address that time applications is point whatever to have replenished in stockpile the – pathogens versus argue before programs participation which threat. align vaccine or one definition having threats, And commercial not threats of real by spectrum points. applications for have

that very thing is focus the broad has today think, if the spectrum. happy So towards be they really one follow that, the evolution shifted about I would

added devices, of much that threats, other throughout based for your out defensive also medical than ever medical have star part There’s definition us beyond points gold If the countermeasures. on documentation legislation position to bioterror some an we're been. pandemic devices is it medical in devices execute literally and cases treatment think And today to non-pharmaceutical we've important better chance a to but application just a In and of you not commercial to are medical most that equation. countermeasure.

Marc Robins

much. I'll get back in queue. Thanks so

Jim Joyce

Thank you.

Jim Frakes

Thank you Mark.

Operator

will the over to remarks. I for crossing for Joyce This concludes back turn allotted reached We have questions. conference Jim now time to our our like question-and-answer session.

Jim Joyce

I appreciate I And look come. continue you forward quarterly call. to the everyone's our you you. in today. to Thank your company in follow hope participation closely to participation Thank months next the again.

Operator

The concluded. Thank now you today's conference for presentation. attending has

You may disconnect. now

Aethlon Medical (AEMD) 4 Nov 172018 Q2 Earnings call transcript